GlassScriptPhysician profile
Don Zwickler
NPI 1255409553
$10,382.41
in general payments reported to CMS, 2019-2025
43 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,913 · 2020: $2,490 · 2021: $56.41 · 2022: $628 · 2023: $775 · 2024: $1,160 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,743.74 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.77 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $475.27 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $462.47 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Lilly USA, LLC | $390.40 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $270.23 | 2019-2025 | |
| Amgen INC. | $251.96 | 2019-2025 | Tepezza, Repatha, Repatha |
| Corcept Therapeutics | $228.32 | 2019-2025 | Korlym |
| Mannkind Corporation | $193.25 | 2019-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $136.00 | 2021-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $130.58 | 2024-2025 | Yorvipath |
| Radius Health, INC. | $112.54 | 2020-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $108.61 | 2022-2025 | Recorlev |
| Abbvie INC. | $99.18 | 2019-2023 | Synthroid, Botox |
| Horizon Therapeutics Plc | $95.85 | 2023 | Tepezza |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Zwickler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.